US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Autonomix Medical Inc

1.48

+0.10007.25%

Post-market: 1.44-0.0400-2.70%19:44 EDT

Volume:197.35K

Turnover:280.14K

Market Cap:4.12M

PE:-0.12

High:1.50

Open:1.37

Low:1.37

Close:1.38

Loading ...

Overview Company News Filings

Autonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan

MT Newswires Live

Autonomix granted approval to expand PoC human clinical trial

Autonomix Medical Inc - Patient Enrollment Expected to Begin in June 2025

THOMSON REUTERS

Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain

THOMSON REUTERS

Autonomix Medical Inc. Reports Uncertain Revenue Outlook Amid Ongoing R&D Expenses; Net Loss Widens as EPS Declines

Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology

THOMSON REUTERS

Autonomix releases testimonial of patient in trial of pancreatic cancer pain

Maxim Group Sticks to Its Buy Rating for Autonomix Medical, Inc. (AMIX)

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain

BRIEF-Autonomix Medical Reports Positive Outcomes In Initial Phase Of First-In-Human Proof-Of-Concept Trial In Pancreatic Cancer Pain And Initiates Market Expansion Study For Visceral Cancer Pain

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

THOMSON REUTERS

Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain

Autonomix Medical Initiated at Buy by Maxim Group

Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target

MT Newswires Live

Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BRIEF-Autonomix Medical Granted New European Patent For Proprietary Catheter-Based Technology

Autonomix engages advisors to guide clinical, regulatory path in cancer pain

Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/AMIX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AMIX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AMIX\",,,,,undefined,":{"symbol":"AMIX","market":"US","secType":"STK","nameCN":"Autonomix Medical Inc","latestPrice":1.48,"timestamp":1749240000000,"preClose":1.38,"halted":0,"volume":197345,"hourTrading":{"tag":"盘后","latestPrice":1.44,"preClose":1.48,"latestTime":"19:44 EDT","volume":4355,"amount":6219.783,"timestamp":1749253449297},"delay":0,"floatShares":2078899,"shares":2780480,"eps":-12.856861,"marketStatus":"Market Closed","change":0.1,"latestTime":"06-06 16:00:00 EDT","open":1.37,"high":1.5,"low":1.37,"amount":280135.7861695,"amplitude":0.094203,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-12.856861,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.38,"preHourTrading":{"tag":"盘前","latestPrice":1.42,"preClose":1.38,"latestTime":"09:24 EDT","volume":6370,"amount":8979.707464000001,"timestamp":1749216270975},"postHourTrading":{"tag":"盘后","latestPrice":1.44,"preClose":1.48,"latestTime":"19:44 EDT","volume":4355,"amount":6219.783,"timestamp":1749253449297},"volumeRatio":0.22675310960005693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AMIX\",,,,,undefined,":{"symbol":"AMIX","floatShares":2078899,"roa":"-75.39%","roe":"-145.10%","lyrEps":-21.093538,"volumeRatio":0.22675310960005693,"shares":2780480,"dividePrice":0,"high":1.5,"amplitude":0.094203,"preClose":1.38,"low":1.37,"week52Low":1.3,"pbRate":"0.51","week52High":42.4,"institutionHeld":0,"latestPrice":1.48,"eps":-12.856861,"divideRate":0,"volume":197345,"delay":0,"ttmEps":-12.856861,"open":1.37,"prevYearClose":3.76,"prevWeekClose":1.625,"prevMonthClose":1.625,"prevQuarterClose":1.75,"fiveDayClose":1.625,"twentyDayClose":1.7,"sixtyDayClose":2.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AMIX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541193079","title":"Autonomix Medical Approved to Begin Testing Treatment for Cancer-Related Pain in Uzbekistan","url":"https://stock-news.laohu8.com/highlight/detail?id=2541193079","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541193079?lang=en_us&edition=fundamental","pubTime":"2025-06-05 22:36","pubTimestamp":1749134188,"startTime":"0","endTime":"0","summary":"Autonomix Medical  said Thursday that regulators in Uzbekistan have approved the start of a clinical trial evaluating the safety and efficacy of using transvascular energy to ablate problematic nerves to mitigate pain in patients with various types of cancer.Autonomix said it is on track to commence enrollment this month.The company previously led proof-of-concept testing of its pain therapy in patients with pancreatic cancer but said it believes its process could eventually be used to treat other conditions, with potential applications for cardiology, gastroenterology and hypertension, as well as treating chronic pain.Autonomix Medical shares were 14% lower in recent trading.Price: 1.38, Change: -0.24, Percent Change: -14.81","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4082","AMIX"],"gpt_icon":0},{"id":"2541395073","title":"Autonomix granted approval to expand PoC human clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2541395073","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541395073?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:50","pubTimestamp":1749127822,"startTime":"0","endTime":"0","summary":"Autonomix (AMIX) Medical has received Ethics Committee authorization from the Ministry of Health of the Republic of Uzbekistan to open the clinical...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autonomix-granted-approval-to-expand-poc-human-clinical-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autonomix-granted-approval-to-expand-poc-human-clinical-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2541707896","title":"Autonomix Medical Inc - Patient Enrollment Expected to Begin in June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2541707896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541707896?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:45","pubTimestamp":1749127530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S807J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2541078964","title":"Autonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2541078964","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541078964?lang=en_us&edition=fundamental","pubTime":"2025-06-05 20:45","pubTimestamp":1749127530,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nFWN3S807J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2539296410","title":"Autonomix Medical Inc. Reports Uncertain Revenue Outlook Amid Ongoing R&D Expenses; Net Loss Widens as EPS Declines","url":"https://stock-news.laohu8.com/highlight/detail?id=2539296410","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539296410?lang=en_us&edition=fundamental","pubTime":"2025-05-30 05:01","pubTimestamp":1748552507,"startTime":"0","endTime":"0","summary":"Autonomix Medical Inc., a development stage medical device company, has released its annual report for the fiscal year ending March 31, 2025. The company is focused on advancing technologies for sensing and treating nervous system disorders, with an initial focus on patients with pancreatic cancer. The report indicates that Autonomix Medical is in the research and development phase and has not yet achieved regulatory approval or commercialization of its device, which means it has not generated revenue from sales. The company's operating expenses are classified into three categories: research and development, general and administrative, and warrant expense - termination agreement. Research and development expenses are primarily driven by costs associated with animal research, design and development of technology, and salaries for employees engaged in these activities. Autonomix Medical highlights the uncertainties involved in obtaining necessary regulatory approvals and the commercializ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250529:nNDLbdRgXL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Autonomix Medical Inc. Reports Uncertain Revenue Outlook Amid Ongoing R&D Expenses; Net Loss Widens as EPS Declines","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMIX"],"gpt_icon":0},{"id":"2535847745","title":"Autonomix Medical, Inc. Granted Key U.S. Patent for Innovative Catheter-Based Platform Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2535847745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535847745?lang=en_us&edition=fundamental","pubTime":"2025-05-15 20:32","pubTimestamp":1747312370,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nFWN3RN17C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","AMIX"],"gpt_icon":0},{"id":"2533581374","title":"Autonomix releases testimonial of patient in trial of pancreatic cancer pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2533581374","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533581374?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:40","pubTimestamp":1746448855,"startTime":"0","endTime":"0","summary":"Autonomix (AMIX) Medical announced the release of a new video testimonial from a patient participating in the initial phase of its first-in-human p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autonomix-releases-testimonial-of-patient-in-trial-of-pancreatic-cancer-pain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autonomix-releases-testimonial-of-patient-in-trial-of-pancreatic-cancer-pain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2533581301","title":"Maxim Group Sticks to Its Buy Rating for Autonomix Medical, Inc. (AMIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2533581301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533581301?lang=en_us&edition=fundamental","pubTime":"2025-05-05 20:37","pubTimestamp":1746448673,"startTime":"0","endTime":"0","summary":"In a report released today, Anthony Vendetti from Maxim Group reiterated a Buy rating on Autonomix Medical, Inc. (AMIX – Research Report), with a p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-autonomix-medical-inc-amix?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-its-buy-rating-for-autonomix-medical-inc-amix?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AMIX"],"gpt_icon":0},{"id":"2532008549","title":"Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2532008549","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532008549?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:25","pubTimestamp":1746105900,"startTime":"0","endTime":"0","summary":"Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses key learnings from initial trial phase  where clinically meaningful pain reduction was demonstrated. Outlines Company’s plans to initiate market expansion study  into additional visceral cancers and earlier stage pancreatic cancer, expected to begin Q2 2025. THE WOODLANDS, TX, May 01, 2025  -- Autonomix Medical, Inc.  , a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it recently participated in a Virtual Investor “What This Means” segment.For the segment, Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discussed the Company’s successfully met initial phase of the first-in-human proof-of-concept trial  and the advancement to a follow-on phase  evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autonomix-medical-inc-nasdaq-amix-132500099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","AMIX","NDAQ"],"gpt_icon":0},{"id":"2531319260","title":"BRIEF-Autonomix Medical Reports Positive Outcomes In Initial Phase Of First-In-Human Proof-Of-Concept Trial In Pancreatic Cancer Pain And Initiates Market Expansion Study For Visceral Cancer Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2531319260","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531319260?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:17","pubTimestamp":1746015475,"startTime":"0","endTime":"0","summary":"BRIEF-Autonomix Medical Reports Positive Outcomes In Initial Phase Of First-In-Human Proof-Of-Concept Trial In Pancreatic Cancer Pain And Initiates Market Expansion Study For Visceral Cancer PainApril","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUABQTWRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2531203194","title":"Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2531203194","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531203194?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUABQTWRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2531031479","title":"Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031479","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031479?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:15","pubTimestamp":1746015300,"startTime":"0","endTime":"0","summary":"Initial trial phase  achieved key learnings and met all study objectives. Company has initiated market expansion study  of additional visceral cancers, and earlier stage pancreatic cancer, to begin in Q2 2025. The Company enrolled twenty  patients in PoC 1, including the first five  “lead-in” patients. Based on consistent, corresponding evidence that successfully met the trial objectives, the Company determined there was a sufficient number of patients and will conclude its initial phase of the study. Notable findings from the study include statistically significant pain relief as early as 24-hours post procedure, providing patients with rapid relief. Pain reduction remained consistently positive at 7-days and 4-6 weeks post-procedure. Patients also reported an improved quality of life during end-stage cancer while reducing their use of opioids, and the procedure demonstrated a strong safety profile. These promising results have led the Company to expand the protocol into a follow-on P","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autonomix-medical-inc-reports-positive-121500546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","AMIX","PACI.U"],"gpt_icon":0},{"id":"2531515758","title":"Autonomix Medical Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2531515758","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531515758?lang=en_us&edition=fundamental","pubTime":"2025-04-29 21:48","pubTimestamp":1745934480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2025 09:48 ET (13:48 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","AMIX"],"gpt_icon":0},{"id":"2531979738","title":"Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2531979738","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531979738?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:12","pubTimestamp":1745928723,"startTime":"0","endTime":"0","summary":"Autonomix Medical (AMIX) has an average rating of Buy and mean price target of $11.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AMIX"],"gpt_icon":0},{"id":"2529828599","title":"Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR","url":"https://stock-news.laohu8.com/highlight/detail?id=2529828599","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529828599?lang=en_us&edition=fundamental","pubTime":"2025-04-24 20:30","pubTimestamp":1745497800,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, TX, April 24, 2025  -- Autonomix Medical, Inc. , a medical device company focused on advancing precision nerve-targeted treatments, today announced its technology and early proof-of-concept study results will be featured in a poster presentation as part of PCR Innovators Day at the world-leading course in interventional cardiovascular medicine, EuroPCR, being held May 20-23, 2025 in Paris, France.About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system vir","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autonomix-medical-inc-technology-early-123000311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AMIX","CSII","PACI.U","BK4082"],"gpt_icon":0},{"id":"2528479776","title":"Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528479776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528479776?lang=en_us&edition=fundamental","pubTime":"2025-04-18 05:00","pubTimestamp":1744923600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA1BS4NQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2528476779","title":"Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2528476779","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528476779?lang=en_us&edition=fundamental","pubTime":"2025-04-18 05:00","pubTimestamp":1744923600,"startTime":"0","endTime":"0","summary":"THE WOODLANDS, TX, April 17, 2025  -- Autonomix Medical, Inc.  , a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Compensation Committee of Autonomix’s Board of Directors approved the grant of an inducement stock option on April 17, 2025 to purchase 5,000 shares of the Company’s common stock, to a new non-executive employee pursuant to the Nasdaq Rule 5635 inducement grant exception, as a component of the individual’s employment compensation and was granted as an inducement material to their start of employment with the Company.The option has an exercise price equal to the closing price of Autonomix’s common stock as reported by the Nasdaq Capital Market on April 17, 2025. The options have a ten-year term and vest in four equal annual installments, subject to the employee’s continued services to the Company through the applicable vesting dates.Although Aut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/autonomix-medical-inc-announces-inducement-210000362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2210150020.SGD","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR",".IXIC","BK4112","BK4588","IE00BKPKM429.USD","BK4585","IE00B64PRP62.GBP","AMIX","NDAQ","IE00B3QW5Z07.USD","BK4082"],"gpt_icon":0},{"id":"2527221145","title":"BRIEF-Autonomix Medical Granted New European Patent For Proprietary Catheter-Based Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2527221145","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527221145?lang=en_us&edition=fundamental","pubTime":"2025-04-16 20:40","pubTimestamp":1744807243,"startTime":"0","endTime":"0","summary":"BRIEF-Autonomix Medical Granted New European Patent For Proprietary Catheter-Based TechnologyApril 16 (Reuters) - Autonomix Medical Inc AMIX.O:AUTONOMIX MEDICAL, INC. GRANTED NEW EUROPEAN PATENT FOR P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250416:nFWN3QU1SC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMIX","BK4082"],"gpt_icon":0},{"id":"2525589454","title":"Autonomix engages advisors to guide clinical, regulatory path in cancer pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2525589454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525589454?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:31","pubTimestamp":1744115467,"startTime":"0","endTime":"0","summary":"Autonomix (AMIX) Medical has engaged U.S. and international-based medical experts in interventional radiology and cancer pain to guide the Company’...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/autonomix-engages-advisors-to-guide-clinical-regulatory-path-in-cancer-pain?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/autonomix-engages-advisors-to-guide-clinical-regulatory-path-in-cancer-pain?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","AMIX"],"gpt_icon":0},{"id":"2525489181","title":"Autonomix Medical, Inc. Engages Leading Medical Experts to Guide U.S. Clinical and Regulatory Path in Pancreatic Cancer Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2525489181","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525489181?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:15","pubTimestamp":1744114500,"startTime":"0","endTime":"0","summary":"Company on track to commence U.S. clinical studies in 2025 to support a De Novo application for FDA approval THE WOODLANDS, TX, April  08, 2025  (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057589/0/en/Autonomix-Medical-Inc-Engages-Leading-Medical-Experts-to-Guide-U-S-Clinical-and-Regulatory-Path-in-Pancreatic-Cancer-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMIX","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AMIX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-10-25","symbol":"AMIX","defaultRemindTime":1729863000000,"type":"split","dateTimestamp":1729828800000,"forFactor":20,"toFactor":1,"ratio":20}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AMIX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AMIX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":2,"updateTime":1745985600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AMIX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AMIX","date":"2025-06-06","current":-0.336289,"percent":0.751553,"low":-13.446357,"twenty":-4.909097,"median":-0.783603,"eighty":-0.31883,"high":-0.216844,"avg":-2.171323,"sd":2.859292,"marketCap":3837062},"quantilePoints":[{"date":"2024-02-02","current":-13.016254,"twenty":-12.020228,"median":-11.748584,"eighty":-11.445249,"marketCap":105524350},{"date":"2024-02-09","current":-11.884406,"twenty":-12.744611,"median":-12.008909,"eighty":-11.694255,"marketCap":96348320},{"date":"2024-02-16","current":-6.689828,"twenty":-12.495604,"median":-11.748584,"eighty":-9.339123,"marketCap":71417101},{"date":"2024-02-23","current":-7.08358,"twenty":-12.26018,"median":-11.476941,"eighty":-6.778064,"marketCap":75620597},{"date":"2024-03-01","current":-7.048515,"twenty":-11.984009,"median":-8.871831,"eighty":-6.901819,"marketCap":75246257},{"date":"2024-03-08","current":-5.374358,"twenty":-11.816495,"median":-7.647447,"eighty":-6.67112,"marketCap":57373836},{"date":"2024-03-15","current":-6.149675,"twenty":-11.757639,"median":-7.066047,"eighty":-6.204039,"marketCap":65650718},{"date":"2024-03-22","current":-5.709154,"twenty":-11.585598,"median":-6.945107,"eighty":-5.652767,"marketCap":60947944},{"date":"2024-03-28","current":-4.880974,"twenty":-11.476941,"median":-6.748784,"eighty":-5.465987,"marketCap":52106730},{"date":"2024-04-05","current":-4.889785,"twenty":-11.413557,"median":-6.607817,"eighty":-5.286254,"marketCap":52200785},{"date":"2024-04-12","current":-4.880974,"twenty":-10.76614,"median":-6.240281,"eighty":-5.025465,"marketCap":52106730},{"date":"2024-04-19","current":-5.021941,"twenty":-9.08499,"median":-5.876552,"eighty":-4.990224,"marketCap":53611617},{"date":"2024-04-26","current":-5.867918,"twenty":-7.772626,"median":-5.709154,"eighty":-5.022575,"marketCap":62642824},{"date":"2024-05-03","current":-5.744396,"twenty":-7.692486,"median":-5.744396,"eighty":-5.029941,"marketCap":61324166},{"date":"2024-05-10","current":-5.356737,"twenty":-7.527625,"median":-5.691533,"eighty":-5.029941,"marketCap":57185725},{"date":"2024-05-17","current":-4.440453,"twenty":-7.242168,"median":-5.559377,"eighty":-4.958506,"marketCap":47403956},{"date":"2024-05-24","current":-4.211382,"twenty":-7.069554,"median":-5.492065,"eighty":-4.893239,"marketCap":44958514},{"date":"2024-05-31","current":-3.735619,"twenty":-7.037907,"median":-5.4096,"eighty":-4.852781,"marketCap":39879519},{"date":"2024-06-07","current":-2.194993,"twenty":-6.985402,"median":-5.365547,"eighty":-4.757628,"marketCap":33859969},{"date":"2024-06-14","current":-1.881328,"twenty":-6.945107,"median":-5.322641,"eighty":-4.687145,"marketCap":29021367},{"date":"2024-06-21","current":-1.404888,"twenty":-6.858532,"median":-5.286254,"eighty":-4.366446,"marketCap":21671800},{"date":"2024-06-28","current":-1.233858,"twenty":-6.819267,"median":-5.285373,"eighty":-4.133851,"marketCap":19033494},{"date":"2024-07-05","current":-0.783683,"twenty":-6.748784,"median":-5.275417,"eighty":-3.96469,"marketCap":12089095},{"date":"2024-07-12","current":-0.708552,"twenty":-6.689828,"median":-5.178943,"eighty":-2.487659,"marketCap":10930125},{"date":"2024-07-15","current":-0.754975,"twenty":-6.680474,"median":-5.144494,"eighty":-2.429126,"marketCap":11646237},{"date":"2024-08-02","current":-1.258291,"twenty":-6.67112,"median":-5.110045,"eighty":-2.392543,"marketCap":19410395},{"date":"2024-08-09","current":-0.8185,"twenty":-6.614866,"median":-5.031544,"eighty":-1.746948,"marketCap":12626179},{"date":"2024-08-16","current":-0.678902,"twenty":-6.530286,"median":-4.969079,"eighty":-1.566951,"marketCap":11717848},{"date":"2024-08-23","current":-0.808829,"twenty":-6.376223,"median":-4.933837,"eighty":-1.243631,"marketCap":13960381},{"date":"2024-08-30","current":-0.766385,"twenty":-6.204039,"median":-4.889785,"eighty":-0.908657,"marketCap":13227806},{"date":"2024-09-06","current":-1.163592,"twenty":-6.121482,"median":-4.880974,"eighty":-0.908419,"marketCap":20083598},{"date":"2024-09-13","current":-1.145173,"twenty":-5.991088,"median":-4.786791,"eighty":-0.966143,"marketCap":19765688},{"date":"2024-09-20","current":-0.869424,"twenty":-5.91708,"median":-4.757628,"eighty":-0.931248,"marketCap":15006258},{"date":"2024-09-27","current":-0.782135,"twenty":-5.89597,"median":-4.695956,"eighty":-0.867778,"marketCap":13499642},{"date":"2024-10-04","current":-0.775461,"twenty":-5.864359,"median":-4.440453,"eighty":-0.840755,"marketCap":13384458},{"date":"2024-10-11","current":-0.783603,"twenty":-5.828976,"median":-4.162925,"eighty":-0.815034,"marketCap":13524983},{"date":"2024-10-18","current":-0.767453,"twenty":-5.744396,"median":-4.017553,"eighty":-0.801154,"marketCap":13246236},{"date":"2024-10-25","current":-0.660676,"twenty":-5.737348,"median":-3.682756,"eighty":-0.798098,"marketCap":11403275},{"date":"2024-10-31","current":-0.683366,"twenty":-5.709154,"median":-2.900189,"eighty":-0.790143,"marketCap":11794903},{"date":"2024-11-08","current":-0.788474,"twenty":-5.691533,"median":-2.37791,"eighty":-0.788808,"marketCap":13609060},{"date":"2024-11-15","current":-0.785853,"twenty":-5.608715,"median":-1.832463,"eighty":-0.788808,"marketCap":11023166},{"date":"2024-11-22","current":-1.110505,"twenty":-5.568187,"median":-1.722515,"eighty":-0.788808,"marketCap":15577054},{"date":"2024-11-29","current":-0.404119,"twenty":-5.554091,"median":-1.649216,"eighty":-0.787206,"marketCap":5668573},{"date":"2024-12-06","current":-0.296518,"twenty":-5.550567,"median":-1.386563,"eighty":-0.783683,"marketCap":4159257},{"date":"2024-12-13","current":-0.258735,"twenty":-5.503765,"median":-1.233858,"eighty":-0.781801,"marketCap":3629269},{"date":"2024-12-20","current":-0.246414,"twenty":-5.426093,"median":-1.173656,"eighty":-0.779652,"marketCap":3456447},{"date":"2024-12-27","current":-0.286661,"twenty":-5.4096,"median":-1.162724,"eighty":-0.772476,"marketCap":4021000},{"date":"2025-01-03","current":-0.276805,"twenty":-5.402552,"median":-1.152867,"eighty":-0.766812,"marketCap":3882742},{"date":"2025-01-10","current":-0.234915,"twenty":-5.388455,"median":-1.126704,"eighty":-0.721272,"marketCap":3295146},{"date":"2025-01-17","current":-0.234915,"twenty":-5.370834,"median":-1.094455,"eighty":-0.690174,"marketCap":3295146},{"date":"2025-01-24","current":-0.245592,"twenty":-5.356737,"median":-1.065091,"eighty":-0.664926,"marketCap":3444925},{"date":"2025-01-31","current":-0.250521,"twenty":-5.323786,"median":-0.993874,"eighty":-0.650158,"marketCap":3514054},{"date":"2025-02-07","current":-0.223415,"twenty":-5.321496,"median":-0.95965,"eighty":-0.514527,"marketCap":3133845},{"date":"2025-02-14","current":-0.234093,"twenty":-5.286254,"median":-0.921104,"eighty":-0.367978,"marketCap":3283624},{"date":"2025-02-21","current":-0.529577,"twenty":-5.286254,"median":-0.884394,"eighty":-0.396891,"marketCap":7216540},{"date":"2025-02-28","current":-0.51331,"twenty":-5.284844,"median":-0.870433,"eighty":-0.404119,"marketCap":6994871},{"date":"2025-03-07","current":-0.451857,"twenty":-5.282659,"median":-0.864124,"eighty":-0.424958,"marketCap":6157457},{"date":"2025-03-14","current":-0.370523,"twenty":-5.271347,"median":-0.855149,"eighty":-0.404119,"marketCap":5049115},{"date":"2025-03-21","current":-0.395827,"twenty":-5.261585,"median":-0.840795,"eighty":-0.370014,"marketCap":5393932},{"date":"2025-03-28","current":-0.345219,"twenty":-5.195119,"median":-0.827514,"eighty":-0.359722,"marketCap":4704297},{"date":"2025-04-04","current":-0.301841,"twenty":-5.123825,"median":-0.816667,"eighty":-0.342327,"marketCap":4113181},{"date":"2025-04-11","current":-0.296418,"twenty":-5.095949,"median":-0.808829,"eighty":-0.326745,"marketCap":4039292},{"date":"2025-04-17","current":-0.319915,"twenty":-5.060707,"median":-0.801955,"eighty":-0.319099,"marketCap":4359479},{"date":"2025-04-25","current":-0.35534,"twenty":-5.029941,"median":-0.800887,"eighty":-0.320999,"marketCap":4842224},{"date":"2025-05-02","current":-0.413901,"twenty":-5.022575,"median":-0.797617,"eighty":-0.323356,"marketCap":5640231},{"date":"2025-05-09","current":-0.307263,"twenty":-4.990224,"median":-0.789475,"eighty":-0.323356,"marketCap":4187071},{"date":"2025-05-16","current":-0.343411,"twenty":-4.958506,"median":-0.788474,"eighty":-0.320999,"marketCap":4679667},{"date":"2025-05-23","current":-0.332567,"twenty":-4.951458,"median":-0.785996,"eighty":-0.321722,"marketCap":4531888},{"date":"2025-05-30","current":-0.301841,"twenty":-4.937361,"median":-0.783988,"eighty":-0.317967,"marketCap":4113181},{"date":"2025-06-06","current":-0.336289,"twenty":-4.909097,"median":-0.783603,"eighty":-0.31883,"marketCap":3837062}],"updateTime":1749374594840}}}